Due to Settlement After Institution of Trial and Granting-in-part and Denying-in-part Joint Motion to Keep Settlement Agreement Separate and Confidential 35 U.S.C. 317; 37 C.F.R. 42.72, 42.74 | May 23, 2023 | PAPER | BOARD |
Ex. 3003 | May 22, 2023 | EXHIBIT | BOARD |
2023-05-16 Motion to Terminate | May 16, 2023 | PAPER | PATENT OWNER |
Motion to Keep Separate and Confidential | May 16, 2023 | PAPER | PATENT OWNER |
EX2083 | May 16, 2023 | EXHIBIT | PATENT OWNER |
Petitioner's Amended Notice of Deposition of Robert Negrin | Apr 28, 2023 | PAPER | PETITIONER |
Petitioner's Notice of Deposition of Adam Bagg | Apr 28, 2023 | PAPER | PETITIONER |
Petitioners' Notice of Deposition of Dr. Robert Negrin | Apr 17, 2023 | PAPER | PETITIONER |
ORDER Granting Petitioners Motion for Additional Discovery 37 C.F.R. sec 42.51 b 2 | Apr 11, 2023 | PAPER | BOARD |
Ex. 3002 | Apr 7, 2023 | EXHIBIT | BOARD |
Patent Owners Opposition to Petitioners Motion for Additional Discovery | Apr 4, 2023 | PAPER | PATENT OWNER |
EX 2082 | Apr 4, 2023 | EXHIBIT | PATENT OWNER |
Petitioner's Motion for Additional Discovery | Mar 21, 2023 | PAPER | PETITIONER |
Petitioner's Objections to Evidence Submitted with Patent Owner's Response | Feb 21, 2023 | PAPER | PETITIONER |
EX 2047 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2048 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2049 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2050 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2051 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2052 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2053 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2054 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2055 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2056 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2057 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2058 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2059 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2060 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2061 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2062 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2063 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2064 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2065 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2066 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2067 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2068 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2069 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2070 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2071 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2072 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2073 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2074 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2075 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2076 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2077 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2078 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2079 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2080 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
EX 2081 | Feb 13, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Exhibit List | Feb 13, 2023 | PAPER | PATENT OWNER |
2023-02-13 Patent Owner Response | Feb 13, 2023 | PAPER | PATENT OWNER |
Second Joint Stipulation to Modify Due Dates 1-3 | Jan 26, 2023 | PAPER | PATENT OWNER |
2022-12-28 Notice of Deposition - Junghans | Dec 28, 2022 | PAPER | PATENT OWNER |
Petitioners' Updated Mandatory Notices | Nov 28, 2022 | PAPER | PETITIONER |
Petitioners' Power of Attorney | Nov 28, 2022 | PAPER | PETITIONER |
Joint Stipulation to Modify Scheduling Order | Nov 11, 2022 | PAPER | PETITIONER |
Patent Owner's Objections to Evidence | Oct 25, 2022 | PAPER | PATENT OWNER |
Petitioner's Objections to Evidence | Oct 25, 2022 | PAPER | PETITIONER |
Institution Decision: Granting Institution of Inter Partes Review 35 U.S.C. sec. 314 | Oct 11, 2022 | PAPER | BOARD |
Order: SCHEDULING ORDER | Oct 11, 2022 | PAPER | BOARD |
Ex. 3001 | Aug 22, 2022 | EXHIBIT | BOARD |
Sur-Reply of Patent Owner and Real Party in Interest | Aug 19, 2022 | PAPER | PATENT OWNER |
POPR Reply | Aug 12, 2022 | PAPER | PETITIONER |
PRELIMINARY RESPONSE OF PATENT OWNER
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
AND REAL PARTY IN INTEREST NOVARTIS PHARMA AG | Jul 19, 2022 | PAPER | PATENT OWNER |
Jason Fagone, Has Carl June Found a Key to Fighting Cancer?, PHILA. MAG. (Aug. 1, 2013). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Denise Grady, An Immune System Trained to Kill Cancer, N.Y. TIMES (Sept. 12, 2011), https://www.nytimes.com/2011/09/13/health/13gene.html. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Jasone Fagone, Walt Keller, Leukemia Survivor, Has Passed, PHILA. MAG. (Feb. 20, 2014), https://www.phillymag.com/news/2014/02/20/walt-keller-leukemia-survivor-obituary-1953-2014/. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Gina Kolata, A Cancer Treatment Makes Leukemia Vanish, but Creates More Mysteries, N.Y. TIMES (Feb. 2, 2022), https://www.nytimes.com/2022/02/02/health/leukemia-car-t-immunotherapy.html. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Denise Grady, In Girl���s Last Hope, Altered Immune Cells Beat Leukemia, N.Y. TIMES (Dec. 9, 2012), https://www.nytimes.com/2012/12/10/health/a-breakthrough-against-leukemia-using-altered-t-cells.html. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Denise Grady, F.D.A. Approves First Gene-Altering Leukemia Treatment, Costing $475,000, N.Y. TIMES (Aug. 30, 2017), https://www.nytimes.com/2017/08/30/health/gene-therapy-cancer.html. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
FOOD AND DRUG ADMIN., FDA APPROVAL BRINGS FIRST GENE THERAPY TO THE UNITED STATES (Aug. 30, 2017), https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
FOOD AND DRUG ADMIN., BREAKTHROUGH THERAPY (Jan. 4, 2018), https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
FOOD AND DRUG ADMIN., PRIORITY REVIEW (Jan. 4, 2018), https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Barbara Savoldo et al., CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients, 121 J. CLINICAL INVESTIGATION 1822 (2011). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Brian G. Till et al., Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, 112 BLOOD 2261 (2008). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Renier J. Brentjens et al., Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, 118 BLOOD 4817 (2011). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Renier Brentjens et al., Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial, 18 MOLECULAR THERAPY 666 (2010). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Renier J. Brentjens et al., A Phase I Trial for the Treatment of Chemo refractory Chronic Lymphocytic Leukemia with CD19-Targeted Autologous T Cells, 16 MOLECULAR THERAPY S15 (2008). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Jennifer Couzin-Frankel, The dizzying journey to a new cancer arsenal, 340 SCI. 1514 (2013). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Jennifer Couzin-Frankel, Breakthrough of the Year 2013: Cancer Immunotherapy, 342 SCI. 1432 (2013). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
David L. Porter et al., Chimeric Antigen Receptor Modified T Cells Directed Against CD 19 (CTL0l 9 cells) Have Long-Term Persistence And Induce Durable Responses In Relapsed, Refractory CLL, 122 BLOOD 4162 (2013). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
David L. Porter et al., Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD 19 (CTL019) In Patients With Relapsed Refractory CLL, 122 BLOOD 873 (2013). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Stephan A. Grupp et al., T Cells Engineered With A Chimeric Antigen Receptor (CAR) Targeting CD 19 (CTL0l 9) Produce Significant In Vivo Proliferation, Complete Responses... 122 BLOOD 67 (2013). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
James N. Kochenderfer et al., B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD 19 chimeric-antigen-receptor transduced T cells, 119 BLOOD 2709 (2012). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Carl June Named One of Time���s 100 Most Influential People in the World, PENN MEDICINE (Apr. 26, 2018), https://pathology.med.upenn.edu/news/carl-june-named-one-times-100-most-influential-people-world. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Holly Auer, Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize, PENN TODAY (Mar. 11, 2015) | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Andrew Pollock, Setting the Body���s ���Serial Killers��� Loose on Cancer, N.Y. TIMES (Aug. 1, 2016), https://www.nytimes.com/2016/08/02/health/cancer-cell-therapy-immune-system.html. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
2015 Watanabe Award Winner Carl H. June, IND. CLINICAL AND TRANSLATIONAL SCIS. INST., https://indianactsi.org/awards/watanabe-award-winners/2015-watanabe-award-winner-carl-h-june/ (last visited July 12, 2022). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Agilent Presents Thought Leader Award to Drs. Carl H. June and Michael Milone, AGILENT TECHS. INC. (Nov. 17, 2020), https://www.agilent.com/about/newsroom/presrel/2020/17nov-ca20030.html. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Information Disclosure Statement Initialed by Examiner (Apr. 18, 2016), U.S. Patent Application No. 14,997,136. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Supplemental Information Disclosure Statement Initialed by Examiner (Apr. 18, 2016), U.S. Patent Application No. 14,997,136. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
World Intell. Prop. Org. Patent Application No. WO 02/077029 A2. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma (CART-19), CLINICALTRIALS.GOV (April 29, 2009), [http://web.archive.org/web/20090903002304/http://clinicaltrials.gov/ct2/show/NCT00891215]. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Amendments to the Claims (Nov. 13, 2018), U.S. Patent Application No. 15,353,899. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Steven A. Rosenberg et al., Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma, 319 NEW ENG. J. MED. 1676 (1988). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Michael C. Jensen et al., Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans, 16 BIOLOGY BLOOD AND MARROW TRANSPLANTATION 1245 (2010). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Richard A. Morgan et al., Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2, 18 MOLECULAR THERAPY 843 (2010). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
David L. Porter et al., A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation, 107 BLOOD 1325 (2006). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Grazyna Lipowska-Bhalla, Targeted immunotherapy of cancer with CAR T cells: achievements and challenges, 61 CANCER IMMUNOLOGY, IMMUNOTHERAPY 953 (2012). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Latest paper from the father of CAR-T: CAR-T really completely cured cancer, MEDICALTREND.ORG, https://medicaltrend.org/2022/02/03/latest-paper-from-the-father-of-car-t-car-t-really-completely-cured-cancer/ (last visited July 13, 2022). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Bipulendu Jena et al., Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, 116 BLOOD 1035 (2010). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Michael H. Kershaw et al., A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer, 12 CLINICAL CANCER RSCH. 6106 (2006). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Cor H.J. Lamers et al., Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience, 24 J. CLINICAL ONCOLOGY e20 (2006). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize, SCIENCEX (Aug. 27, 2012), https://sciencex.com/wire-news/107531358/ash-honors-bruce-r-blazar-md-and-carl-h-june-md-with-2012-ernest.html. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Renier J. Brentjens et al., Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts, 13 CLINICAL CANCER RSCH. 5426 (2007). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
U.S. Patent No. 7,402,431. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Cancer treatment myths: Any truth to these common beliefs?, MAYO CLINIC (March 22, 2022), https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer/art-20046762. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
Adam Bagg Aff., July 19, 2022. | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
SITC Smalley Award 2013 Recipient, SOC���Y FOR IMMUNOTHERAPY OF CANCER, https://www.sitcancer.org/funding/named-funds-and-awards2/smalley/2013 (last visited July 19, 2022). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
AAI-Steinman Award for Human Immunology Research Past Recipients, AM. ASS���N OF IMMUNOLOGISTS, https://www.aai.org/Awards/Career-Awards/AAI-Steinman-Award-for-Human-Immunology-Research/Past-Recipients.aspx (last visited July 19, 2022). | Jul 19, 2022 | EXHIBIT | PATENT OWNER |
IPR2022-00855 Mandatory Notices by Patent Owner | May 2, 2022 | PAPER | PATENT OWNER |
Power of Attorney | May 2, 2022 | PAPER | PATENT OWNER |
Notice: Notice filing date accorded | Apr 19, 2022 | PAPER | BOARD |
Arnold Declaration | Apr 19, 2022 | EXHIBIT | PETITIONER |
445 Petition | Apr 12, 2022 | PAPER | PETITIONER |
445 Petition - POA | Apr 12, 2022 | PAPER | PETITIONER |
Exhibit List | Apr 12, 2022 | PAPER | PETITIONER |
9,540,445 Patent | Apr 12, 2022 | EXHIBIT | PETITIONER |
Junghans Decl | Apr 12, 2022 | EXHIBIT | PETITIONER |
Campana | Apr 12, 2022 | EXHIBIT | PETITIONER |
Nicholson | Apr 12, 2022 | EXHIBIT | PETITIONER |
Honsik | Apr 12, 2022 | EXHIBIT | PETITIONER |
CART-19 ClinicalTrials.gov - Internet Archive Decl and Exhibit | Apr 12, 2022 | EXHIBIT | PETITIONER |
Jensen | Apr 12, 2022 | EXHIBIT | PETITIONER |
Milone | Apr 12, 2022 | EXHIBIT | PETITIONER |
Littman | Apr 12, 2022 | EXHIBIT | PETITIONER |
Sadelain | Apr 12, 2022 | EXHIBIT | PETITIONER |
Riddell | Apr 12, 2022 | EXHIBIT | PETITIONER |
Porter | Apr 12, 2022 | EXHIBIT | PETITIONER |
Porter Protocol | Apr 12, 2022 | EXHIBIT | PETITIONER |
PCT/US2011/064191 File History Excerpts | Apr 12, 2022 | EXHIBIT | PETITIONER |
U.S. Provisional Application 61/502,649 File History | Apr 12, 2022 | EXHIBIT | PETITIONER |
U.S. Provisional Application 61/421,470 File History | Apr 12, 2022 | EXHIBIT | PETITIONER |
445 Patent File History excerpts | Apr 12, 2022 | EXHIBIT | PETITIONER |
Imai | Apr 12, 2022 | EXHIBIT | PETITIONER |
Ng | Apr 12, 2022 | EXHIBIT | PETITIONER |
SIFT webpage - Internet Archive Decl and Exhibit | Apr 12, 2022 | EXHIBIT | PETITIONER |
Turco | Apr 12, 2022 | EXHIBIT | PETITIONER |
Dudrick | Apr 12, 2022 | EXHIBIT | PETITIONER |
Porter Correction | Apr 12, 2022 | EXHIBIT | PETITIONER |
U.S. Patent Application No. 15/353,899 File History Excerpts | Apr 12, 2022 | EXHIBIT | PETITIONER |
Immunobiology | Apr 12, 2022 | EXHIBIT | PETITIONER |
Molecular Biology | Apr 12, 2022 | EXHIBIT | PETITIONER |
Jena | Apr 12, 2022 | EXHIBIT | PETITIONER |
Klebanoff | Apr 12, 2022 | EXHIBIT | PETITIONER |
Huston | Apr 12, 2022 | EXHIBIT | PETITIONER |
Mosteller | Apr 12, 2022 | EXHIBIT | PETITIONER |
McDowell | Apr 12, 2022 | EXHIBIT | PETITIONER |
Boursier | Apr 12, 2022 | EXHIBIT | PETITIONER |
Sukhatme | Apr 12, 2022 | EXHIBIT | PETITIONER |
NCT01029366 webpage | Apr 12, 2022 | EXHIBIT | PETITIONER |
Porter Protocol - Sept 24 2011 | Apr 12, 2022 | EXHIBIT | PETITIONER |
Porter Protocol - April 22 2012 | Apr 12, 2022 | EXHIBIT | PETITIONER |
Schneider | Apr 12, 2022 | EXHIBIT | PETITIONER |
U.S. Patent No. 8,911,993 File History Excerpts | Apr 12, 2022 | EXHIBIT | PETITIONER |
Zhao | Apr 12, 2022 | EXHIBIT | PETITIONER |
Kochenderfer 2010 | Apr 12, 2022 | EXHIBIT | PETITIONER |
Brentjens | Apr 12, 2022 | EXHIBIT | PETITIONER |
Davila | Apr 12, 2022 | EXHIBIT | PETITIONER |
Kochenderfer 2009 | Apr 12, 2022 | EXHIBIT | PETITIONER |
Mead | Apr 12, 2022 | EXHIBIT | PETITIONER |
Arnold Declaration | Apr 12, 2022 | EXHIBIT | PETITIONER |